Rebecca Lynn Porter, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 4 | 2023 | 4838 | 1.040 |
Why?
|
| RNA, Satellite | 1 | 2022 | 17 | 0.870 |
Why?
|
| Hematopoietic Stem Cells | 6 | 2013 | 3386 | 0.570 |
Why?
|
| Immunoconjugates | 1 | 2023 | 901 | 0.540 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 90 | 0.430 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2013 | 91 | 0.430 |
Why?
|
| Dinoprostone | 2 | 2013 | 600 | 0.430 |
Why?
|
| Osteoblasts | 4 | 2012 | 1166 | 0.310 |
Why?
|
| Immunotherapy | 1 | 2022 | 4445 | 0.280 |
Why?
|
| Osteocytes | 1 | 2008 | 197 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 546 | 0.270 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 2513 | 0.250 |
Why?
|
| Bone Marrow | 2 | 2009 | 2948 | 0.200 |
Why?
|
| Hematopoiesis | 3 | 2012 | 2072 | 0.200 |
Why?
|
| Cell Communication | 1 | 2008 | 1621 | 0.190 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 13695 | 0.180 |
Why?
|
| Macrophages | 1 | 2013 | 5655 | 0.160 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 713 | 0.150 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 4456 | 0.140 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 255 | 0.120 |
Why?
|
| Puerperal Disorders | 1 | 2016 | 275 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2022 | 1580 | 0.110 |
Why?
|
| RNA | 1 | 2022 | 2749 | 0.100 |
Why?
|
| Whole-Body Irradiation | 1 | 2013 | 449 | 0.100 |
Why?
|
| RNA, Antisense | 1 | 2011 | 138 | 0.090 |
Why?
|
| RNA, Fungal | 1 | 2011 | 164 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 611 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3586 | 0.090 |
Why?
|
| Schizosaccharomyces pombe Proteins | 1 | 2011 | 178 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 8642 | 0.090 |
Why?
|
| Schizosaccharomyces | 1 | 2011 | 237 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 5172 | 0.080 |
Why?
|
| Methyltransferases | 1 | 2011 | 367 | 0.080 |
Why?
|
| Cadherins | 1 | 2012 | 907 | 0.070 |
Why?
|
| Erythroblasts | 1 | 2007 | 150 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 8428 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 16689 | 0.070 |
Why?
|
| Actins | 1 | 2013 | 2121 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9239 | 0.060 |
Why?
|
| Phenotype | 1 | 2022 | 16365 | 0.060 |
Why?
|
| Erythropoiesis | 1 | 2007 | 705 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 9734 | 0.060 |
Why?
|
| Cell Survival | 1 | 2013 | 5882 | 0.050 |
Why?
|
| RNA Interference | 1 | 2011 | 2889 | 0.050 |
Why?
|
| Female | 5 | 2023 | 380194 | 0.050 |
Why?
|
| Fetus | 1 | 2007 | 1880 | 0.040 |
Why?
|
| Humans | 7 | 2023 | 744343 | 0.040 |
Why?
|
| Gene Expression | 1 | 2013 | 7799 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 3462 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2008 | 2504 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 2942 | 0.040 |
Why?
|
| Mice | 5 | 2013 | 81183 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2013 | 11483 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5221 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10481 | 0.040 |
Why?
|
| Animals | 6 | 2013 | 168757 | 0.040 |
Why?
|
| Apoptosis | 1 | 2013 | 9727 | 0.040 |
Why?
|
| Peripartum Period | 1 | 2016 | 133 | 0.030 |
Why?
|
| Osteoclasts | 2 | 2009 | 729 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13102 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2012 | 386 | 0.020 |
Why?
|
| Euchromatin | 1 | 2011 | 56 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 1179 | 0.020 |
Why?
|
| Centromere | 1 | 2011 | 220 | 0.020 |
Why?
|
| Bone and Bones | 2 | 2012 | 2575 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2009 | 356 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 1660 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2012 | 575 | 0.020 |
Why?
|
| Methylation | 1 | 2011 | 1106 | 0.020 |
Why?
|
| Yolk Sac | 1 | 2007 | 75 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 436 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 242 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2007 | 352 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 670 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1801 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 23403 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 21827 | 0.010 |
Why?
|
| Embryonic Development | 1 | 2007 | 711 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 1903 | 0.010 |
Why?
|
| Genotype | 1 | 2016 | 12951 | 0.010 |
Why?
|
| Adipocytes | 1 | 2008 | 1184 | 0.010 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 1888 | 0.010 |
Why?
|
| Pregnancy | 2 | 2016 | 29144 | 0.010 |
Why?
|
| Base Sequence | 1 | 2012 | 12797 | 0.010 |
Why?
|
| Histones | 1 | 2011 | 2599 | 0.010 |
Why?
|
| Male | 3 | 2013 | 350118 | 0.010 |
Why?
|
| Bone Density | 1 | 2012 | 3468 | 0.010 |
Why?
|
| Graft Survival | 1 | 2009 | 3737 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2012 | 13033 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2008 | 1832 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 2529 | 0.010 |
Why?
|
| Aging | 1 | 2012 | 8664 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 5442 | 0.010 |
Why?
|
| Neurons | 1 | 2008 | 9338 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 77449 | 0.000 |
Why?
|
| Mutation | 1 | 2011 | 29786 | 0.000 |
Why?
|
| Adult | 1 | 2016 | 214055 | 0.000 |
Why?
|